Cargando…

Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met

INTRODUCTION: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have shown clinical efficacy in lung, colon, and pancreatic cancers. In lung cancer, resistance to EGFR TKIs correlates with amplification of the hepatocyte growth factor (HGF) receptor tyrosine kinase Met. Breas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mueller, Kelly L, Madden, Julie M, Zoratti, Gina L, Kuperwasser, Charlotte, List, Karin, Boerner, Julie L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3680928/ https://www.ncbi.nlm.nih.gov/pubmed/22788954 http://dx.doi.org/10.1186/bcr3224

Ejemplares similares

Paracrine Regulation of Germinal Center B Cell Adhesion through the c-Met–Hepatocyte Growth Factor/Scatter Factor Pathway
por: van der Voort, Robbert, et al.
Publicado: (1997)

Hepatocyte Growth Factor Modulates MET Receptor Tyrosine Kinase and β-Catenin Functional Interactions to Enhance Synapse Formation
por: Xie, Zhihui, et al.
Publicado: (2016)

Targeting matriptase in breast cancer abrogates tumor progression via impairment of stromal-epithelial growth factor signaling
por: Zoratti, Gina L., et al.
Publicado: (2015)

Hepatocyte growth factor/MET in cancer progression and biomarker discovery
por: Matsumoto, Kunio, et al.
Publicado: (2017)

The Met receptor tyrosine kinase transduces motility, proliferation, and morphogenic signals of scatter factor/hepatocyte growth factor in epithelial cells
Publicado: (1993)

Matriptase regulates c-Met mediated proliferation and invasion in inflammatory breast cancer
por: Zoratti, Gina L., et al.
Publicado: (2016)

Epidermal growth factor receptor tyrosine kinase inhibitors
por: Ranson, M
Publicado: (2004)

Associations between hepatocyte growth factor, c-Met, and basic fibroblast growth factor and survival in endometrial cancer patients
por: Felix, A S, et al.
Publicado: (2012)

Hepatocyte growth factor reduces sensitivity to the epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib, in lung adenocarcinoma cells harboring wild-type EGFR
por: Yang, Hua, et al.
Publicado: (2016)

Paracrine effects of hepatocyte growth factor/scatter factor on non-small-cell lung carcinoma cell lines.
por: Yi, S., et al.
Publicado: (1998)

Roles of hepatocyte growth factor/scatter factor and the met receptor in the early development of the metanephros
Publicado: (1995)

Caspase-mediated proteolysis of the sorting nexin 2 disrupts retromer assembly and potentiates Met/hepatocyte growth factor receptor signaling
por: Duclos, Catherine M, et al.
Publicado: (2017)

Hepatocyte Growth Factor/c-Met Signaling Is Required for β-Cell Regeneration
por: Alvarez-Perez, Juan Carlos, et al.
Publicado: (2014)

Targeting the Hepatocyte Growth Factor and c-Met Signaling Axis in Bone Metastases
por: Whang, Young Mi, et al.
Publicado: (2019)

The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer
por: Chang, Shih-Chieh, et al.
Publicado: (2011)

Protein Expression of DNA Damage Repair Proteins Dictates Response to Topoisomerase and PARP Inhibitors in Triple-Negative Breast Cancer
por: Boerner, Julie L., et al.
Publicado: (2015)

Inhibiting Epidermal Growth Factor Receptor at a Distance
por: Sinclair, Julie K.-L., et al.
Publicado: (2014)

Sensitivities to various epidermal growth factor receptor‐tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor‐tyrosine kinase inhibitor?
por: Banno, Eri, et al.
Publicado: (2016)

The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment
por: Parikh, Rahul A, et al.
Publicado: (2014)

Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors
por: Smyth, Elizabeth C, et al.
Publicado: (2014)

Functional and therapeutic relevance of hepatocyte growth factor/c‐MET signaling in synovial sarcoma
por: Imura, Yoshinori, et al.
Publicado: (2016)

Editorial of Special Issue “New Aspects of the Hepatocyte Growth Factor/c-Met System”
por: Ricci, Giulia
Publicado: (2015)

Hepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for Treatment
por: Rothenberger, Natalie J., et al.
Publicado: (2017)

Receptor-mediated endocytosis of epidermal growth factor by rat hepatocytes: receptor pathway
Publicado: (1986)

Radiosensitization of glioma cells by modulation of Met signalling with the hepatocyte growth factor neutralizing antibody, AMG102
por: Buchanan, Ian M, et al.
Publicado: (2011)

Extracellular superoxide dismutase inhibits hepatocyte growth factor-mediated breast cancer-fibroblast interactions
por: Golden, Briana Ormsbee, et al.
Publicado: (2017)

Heparin-binding epidermal growth factor-like growth factor and hepatocyte growth factor inhibit cholestatic liver injury in mice through different mechanisms
por: Sakamoto, Kouichi, et al.
Publicado: (2016)

Hepatocyte Growth Factor and Cardiac Amyloidosis
por: Ruberg, Frederick L., et al.
Publicado: (2020)

The hepatocyte growth factor/c-met pathway is a key determinant of the fibrotic kidney local microenvironment
por: Fu, Haiyan, et al.
Publicado: (2021)

Mesenchymal stem cell and endothelial cell interaction restores endothelial permeability via paracrine hepatocyte growth factor in vitro
por: Chen, Q, et al.
Publicado: (2015)

A High Affinity Hepatocyte Growth Factor-binding Site in the Immunoglobulin-like Region of Met
por: Basilico, Cristina, et al.
Publicado: (2008)

Does hepatocyte growth factor/c-Met signal play synergetic role in lung cancer?
por: Wang, Xiangdong, et al.
Publicado: (2010)

Clinical significance of hepatocyte growth factor/c-Met expression in the assessment of gastric cancer progression
por: NOGUCHI, EIICHIRO, et al.
Publicado: (2015)

Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma
por: Johnson, Jennifer, et al.
Publicado: (2015)

Updates on the hepatocyte growth factor/c-Met axis in hepatocellular carcinoma and its therapeutic implications
por: García-Vilas, Javier A, et al.
Publicado: (2018)

Expression and functional interaction of hepatocyte growth factor- scatter factor and its receptor c-met in mammalian brain
Publicado: (1994)

Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2
por: Tanaka, Hidekazu, et al.
Publicado: (2014)

Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types
por: Park, Sojung, et al.
Publicado: (2021)

A case of epidermal growth factor receptor tyrosine kinase inhibitor effectiveness in epidermal growth factor receptor mutation-positive squamous cell carcinoma
por: Matsumura, Sosuke, et al.
Publicado: (2023)

MET Gene Copy Number Alterations and Expression of MET and Hepatocyte Growth Factor Are Potential Biomarkers in Angiosarcomas and Undifferentiated Pleomorphic Sarcomas
por: Schmitz, Katja, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_6nqlvrlq9m00r2gkhlefsudsum